PUBLIC COMPANY
save$TENXTENAX THERAPEUTICS, INC.
$TENXChapel Hill, NC, USupdated 17d ago
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients
- phase3Long-Term Open-Label Extension Study of Oral Levosimendan
- phase3LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
- phase2Study of Oxycyte in Severe Closed Head Injury
- phase3LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
- phase2Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF
🐶 Hiring Signal
News
- Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75MPlus news about Tenax Therapeutics, Aureka Biotechnologies, ATyr Pharma, Prana Therapies and Mereo BioPharma. 💸 Lilly’s vaccine acquisitions: In May, Eli Lilly said it would pay up to $3.8 billion…endpoints · 6d ago
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that